What this study is
The purpose of this research study is to evaluate the safety and outcomes associated with the use of IRRAflow® System catheters in externally draining intracranial fluid to reduce intracranial pressure. This study will be comparing the IRRAflow® system to standard of care catheters used in the same procedure. The IRRAflow® system is FDA approved for this procedure.
What's being tested
- IRRAflow® Active Fluid Exchange System
Intervention · DEVICE
All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm. Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise.
- Traditional extraventricular drain
Intervention · DEVICE
The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
- Non-contrast head CTs
Intervention · PROCEDURE
Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.
Study details
- Official title
- DIVE: Deployment of Irrigating Intraventricular Catheter System for Intraventricular Hemorrhage
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Intraventricular Hemorrhage (IVH)
- Enrolling
- 17 people
- Starts
- 2022-06-14
- Est. completion
- 2026-12-31
- Design
- Open-label, non-randomized, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age >=18 years of age
- Intraventricular hemorrhage documented on head CT or MRI scan
- Need of cerebrospinal fluid drainage
- Indication for active treatment evaluated by the treating physicians
- Signed informed consent obtained by patient or Legal Authorized Representative
- Treatment possible within 72 hours of ictus
You can't join if
- Patient has fixed and dilated pupils
- Pregnant or nursing women (fertile female participants will be required to take a validated pregnancy test for evaluation of pregnancy)
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openIcahn School of Medicine at Mount Sinai
New York, New York, United States
- Christopher P Kellner, MD · Contact212-241-2606christopher.kellner@mountsinai.org
- Trevor Hardigan, MD PhD · Contact212-241-2606trevor.hardigan@mountsinai.org
- Christopher P Kellner · Principal investigator
Recruiting
Study team
Sponsor
Icahn School of Medicine at Mount Sinai
Study ID STUDY-21-01815
Principal investigator
Christopher P Kellner, MD
Icahn School of Medicine at Mount Sinai
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.